Atara Biotherapeutics
ATRA
90 hedge funds and large institutions have $33.2M invested in Atara Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 35 closing their positions.
0.95% less ownership
Funds ownership: 3.49% → 2.54% (-0.95%)
9% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 32
15% less call options, than puts
Call options by funds: $23K | Put options by funds: $27K
17% less funds holding
Funds holding: 109 → 90 (-19)
51% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 35
75% less capital invested
Capital invested by funds: $131M → $33.2M (-$97.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.39M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.39M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$2.64M |
| 4 |
Millennium Management
New York
|
+$2.42M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$14.5M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$12.4M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$9.31M |
| 4 |
JP Morgan Chase
New York
|
-$6.04M |
| 5 |
Goldman Sachs
New York
|
-$3.3M |
ATRA Hedge Fund Activity: Q4 2023 in Review
90 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2023, worth a combined $33.2M — down 75% from $131M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ATRA and 17 opened new positions — a net loss of 18 holders — while 32 trimmed existing stakes and 29 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.39M. The largest seller was Baupost Group, exiting entirely with an estimated $14.5M sold.
- 90 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2023, down from 109 in Q3 2023.
- Funds reported $33.2M of Atara Biotherapeutics stock for Q4 2023, down 75% quarter-over-quarter.
- 17 funds opened new Atara Biotherapeutics positions in Q4 2023 and 35 closed out, a net change of -18 holders.
- The largest Atara Biotherapeutics buyer in Q4 2023 was EcoR1 Capital, an estimated $9.39M added.
- The largest Atara Biotherapeutics seller in Q4 2023 was Baupost Group, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2023.